damage.' For this reason there is much current interest in the use of thrombolysis in the management of acute myocardial infarction. Reperfusion of the infarct related coronary artery by a direct intracoronary infusion of agents such as streptokinase occurs in approximately 75% of patients.24 Some studies have shown improvement in left ventricular function5 and short term survival. 6 The application of intracoronary thrombolysis is, however, limited because it requires facilities for emergency coronary angiography, which are not widely available, particularly outside normal working hours.
Intravenous administration of a thrombolytic agent is a more practical approach. Early studies of 24 hour infusion regimens produced inconsistent results7'8 and this treatment was not generally accepted. More recent trials have shown that high dose infusions of shorter duration produce a rate of clot lysis of approximately 60% 3 -a rate that is only slightly lower than that obtained with intracoronary administration. Indeed, some workers believe that ultimately clot lysis may occur as frequently with intravenous as with intracoronary administration.39
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Accepted for publication 15 September 1986 Good responses in left ventricular function'0 and short term survival'1 have been achieved by both methods. Intravenous administration has, therefore, been put forward as a technique that could be generally applied in clinical practice.
Certain problems may limit the use of thrombolytic treatment. Firstly, patients must be selected with care if haemorrhage and hypersensitivity are to be avoided. Secondly, thrombolysis should probably be performed within six hours of the onset of symptoms' if myocardial salvage is to be achieved.
Even in well equipped centres treatment will be delayed to allow for the coronary angiography that is required before intracoronary thrombolysis can be performed. The inverse relation between the amount of myocardial salvage and the time between coronary occlusion and clot lysis makes the intravenous route more attractive. Prehospital delays may, however, be as important as in hospital ones, and they apply equally to intravenous and intracoronary administration. Thus it may be that although intravenous thrombolysis has been widely advocated, it may not be as applicable as was at first thought.
We are currently engaged in a multicentre trial to investigate the role of high dose intravenous streptokinase in suspected myocardial infarction. We report the reasons for the exclusion of patients from the trial. This should indicate the proportion of patients with suspected myocardial infarction who will be suitable for thrombolysis. 1). The most important reasons for exclusion were history of peptic ulceration, systemic hypertension, and resuscitation.
Thus 98 (24%) patients were suitable for thrombolysis. Of these, 42 were over the age of 70 years and were excluded on this criterion alone. Therefore, 56 (14%) patients were eligible for recruitment. Finally 36 (9%) were recruited. The reasons for the exclusion of the remaining 20 were inability to obtain consent in six patients, cardiac arrest before randomisation in two, and local administrative reasons in twelve.
Discussion
These data suggest that only a small proportion of patients with acute myocardial infarction are suitable for thrombolysis if the criteria used in this study are applied. This has two implications. First, any conclusions about efficacy of thrombolysis can only be applied to this group of patients. Secondly, if thrombolysis becomes clinically useful it may be inappropriate for over three quarters of all patients with myocardial infarction. This does not reduce the Murray, Lyons, Layton, Balcon value of thrombolysis in patients who are suitable and in whom it may prove to be very useful.
The problem of patient recruitment is common to many thrombolysis trials. Khaja et al recruited 54 (18%) of a possible 305 patients into a trial of intracoronary streptokinase.'2 There was no upper age limit in this protocol, although patients had to present within six hours of the onset of symptoms. The European cooperative trial of intravenous streptokinase, published in 1979, set a time limit of 12 hours from symptom onset and required a birthdate of 1900 or later for inclusion.8 These workers stratified 512 (22%) of 2338 patients and finally randomised 315 (13-5%). In the treatment group there were 31 patients (12 streptokinase, 19 placebo) in whom the 12 hour limit was exceeded. A recent study by Sainsous et al reported that of 1105 patients with myocardial infarction 175 (15-8%) were suitable for intravenous thrombolysis. 13 Low recruitment rates are a feature of other infarct intervention studies. Lie et al recruited 29% of all patients with infarcts into a trial of lignocaine,1' Yusuf et al randomised 10-20% of all possible patients into a trial of atenolol,15 and Muller et al recruited 8% into a study of nifedipine.'6 Contraindications to treatment varied in the trial protocols but important factors for the low recruitment rates in all these trials were the age of the patients and the time taken for them to present.
Attempts to widen the application of thrombolysis could be aimed at the reasons for exclusion of patients as described above. If the treatment is to remain safe, however, the number of patients with contraindications to specific treatments with different thrombolytics is unlikely to be reduced. 
